Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
September 19, 2017 08:00 ET
|
Spring Bank Pharmaceuticals Inc.
Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist HOPKINTON, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH),...
Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference
September 13, 2017 08:00 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.
August 28, 2017 08:30 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results
July 31, 2017 16:15 ET
|
Spring Bank Pharmaceuticals Inc.
Reports multiple recent developments and milestones Plans to report top-line results from the second monotherapy dosing cohort of the ACHIEVE global Phase 2 clinical trial of SB 9200 in chronic HBV...
Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
July 10, 2017 08:30 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock
June 22, 2017 09:00 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 21, 2017 16:00 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
June 07, 2017 07:00 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was published at the...
Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
May 23, 2017 16:00 ET
|
Spring Bank Pharmaceuticals Inc.
SB 9200 Shows Favorable Safety Profile and Significant Antiviral Activity Against HBV DNA and HBsAg with Initial Low Dose Monotherapy of 25mg Conference Call Scheduled for Tomorrow, May 24th...
Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial
May 22, 2017 16:00 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...